J&J’s DePuy Synthes launches TFNA hip repair system

This article was originally published here

DePuy Synthes

Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes said today it launched the TFNA augmentation system designed to treat patients with hip fractures who have poor bone quality.

The company touted the system as the 1st and only polymethylmethacrylate cement with indications for specific traumas. The system is designed to be used to enhance implant fixation in cases where there is a significant potential risk of cut-out.

“The TFNA Augmentation System addresses an important clinical need for patients who undergo hip fracture surgery, especially those who suffer from poor bone quality. This new system complements the TFNA System and has the potential to improve patient outcomes, reduce costs, and increase patient satisfaction,” DePuy Synthes trauma franchise medical leader Dr. Charisse Sparks said in a prepared statement.

Earlier this month, DePuy Synthes said it launched the Maxframe multi-axial limb correction system designed to gradually correct bone or soft tissue deformities in the arm, leg, foot or ankle.

DePuy said the Maxframe system includes 3D planning software intended to create accurate patient treatment plans and reduce the number of X-rays required and the procedural complexity of treatments.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply